Surface Oncology, Inc. Common Stock
SURF
SURF was delisted on the 7th of September, 2023.
90 hedge funds and large institutions have $147M invested in Surface Oncology, Inc. Common Stock in 2021 Q1 according to their latest regulatory filings, with 26 funds opening new positions, 31 increasing their positions, 19 reducing their positions, and 24 closing their positions.
63% more repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 19
12% more call options, than puts
Call options by funds: $3.39M | Put options by funds: $3.03M
8% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 24
1% less funds holding
Funds holding: 91 → 90 (-1)
31% less capital invested
Capital invested by funds: $213M → $147M (-$65.9M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$15.3M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$8.87M |
| 3 |
Goldman Sachs
New York
|
+$4.94M |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
+$3.32M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$2.06M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VA
VR Adviser
New York
|
-$13.3M |
| 2 |
GTC
Ghost Tree Capital
New York
|
-$9.24M |
| 3 |
ACP
Acuta Capital Partners
Redwood City,
California
|
-$9.23M |
| 4 |
Morgan Stanley
New York
|
-$8.65M |
| 5 |
CC
Commodore Capital
New York
|
-$4.32M |
SURF Hedge Fund Activity: Q1 2021 in Review
90 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Surface Oncology, Inc. Common Stock (SURF) for Q1 2021, worth a combined $147M — down 31% from $213M a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new SURF positions and 24 closed out — a net gain of 2 holders — while 31 added to existing stakes and 19 trimmed.
The largest buyer was ARK Investment Management, adding an estimated $15.3M. The largest seller was VR Adviser, exiting entirely with an estimated $13.3M sold.
- 90 institutional investors held Surface Oncology, Inc. Common Stock (SURF) as of Q1 2021, down from 91 in Q4 2020.
- Funds reported $147M of Surface Oncology, Inc. Common Stock stock for Q1 2021, down 31% quarter-over-quarter.
- 26 funds opened new Surface Oncology, Inc. Common Stock positions in Q1 2021 and 24 closed out, a net change of +2 holders.
- The largest Surface Oncology, Inc. Common Stock buyer in Q1 2021 was ARK Investment Management, an estimated $15.3M added.
- The largest Surface Oncology, Inc. Common Stock seller in Q1 2021 was VR Adviser, an estimated $13.3M sold.
Based on aggregated 13F filings for Q1 2021.